Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arantzazu Campo is active.

Publication


Featured researches published by Arantzazu Campo.


American Journal of Respiratory and Critical Care Medicine | 2015

Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. Development and Validation of the COPD Lung Cancer Screening Score

Juan P. de-Torres; David O. Wilson; Pablo Sanchez-Salcedo; Joel L. Weissfeld; Juan Berto; Arantzazu Campo; Ana B. Alcaide; Marta García-Granero; Bartolome R. Celli; Javier J. Zulueta

RATIONALE Patients with chronic obstructive pulmonary disease (COPD) are at high risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs. OBJECTIVES To develop a predictive score for LC risk for patients with COPD. METHODS The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD LC screening score (COPD-LUCSS) to be validated in P-IELCAP. MEASUREMENTS AND MAIN RESULTS By regression analysis, age greater than 60, body mass index less than 25 kg/m(2), pack-years history greater than 60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS, which ranges from 0 to 10 points. Two COPD-LUCSS risk categories were proposed: low risk (scores 0-6) and high risk (scores 7-10). In comparison with low-risk patients, in both cohorts LC risk increased 3.5-fold in the high-risk category. CONCLUSIONS The COPD-LUCSS is a good predictor of LC risk in patients with COPD participating in LC screening programs. Validation in two different populations adds strength to the findings.


American Journal of Respiratory and Critical Care Medicine | 2015

Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema

Pablo Sanchez-Salcedo; David O. Wilson; Juan P. de-Torres; Joel L. Weissfeld; Juan Berto; Arantzazu Campo; Ana B. Alcaide; Jesús C. Pueyo; Gorka Bastarrika; Luis Seijo; Maria J. Pajares; Ruben Pio; Luis M. Montuenga; Javier J. Zulueta

RATIONALE Lung cancer (LC) screening using low-dose chest computed tomography is now recommended in several guidelines using the National Lung Screening Trial (NLST) entry criteria (age, 55-74; ≥30 pack-years; tobacco cessation within the previous 15 yr for former smokers). Concerns exist about their lack of sensitivity. OBJECTIVES To evaluate the performance of NLST criteria in two different LC screening studies from Europe and the United States, and to explore the effect of using emphysema as a complementary criterion. METHODS Participants from the Pamplona International Early Lung Action Detection Program (P-IELCAP; n = 3,061) and the Pittsburgh Lung Screening Study (PLuSS; n = 3,638) were considered. LC cumulative frequencies, incidence densities, and annual detection rates were calculated in three hypothetical cohorts, including subjects who met NLST criteria alone, those with computed tomography-detected emphysema, and those who met NLST criteria and/or had emphysema. MEASUREMENTS AND MAIN RESULTS Thirty-six percent and 59% of P-IELCAP and PLuSS participants, respectively, met NLST criteria. Among these, higher LC incidence densities and detection rates were observed. However, applying NLST criteria to our original cohorts would miss as many as 39% of all LC. Annual screening of subjects meeting either NLST criteria or having emphysema detected most cancers (88% and 95% of incident LC of P-IELCAP and PLuSS, respectively) despite reducing the number of screened participants by as much as 52%. CONCLUSIONS LC screening based solely on NLST criteria could miss a significant number of LC cases. Combining NLST criteria and emphysema to select screening candidates results in higher LC detection rates and a lower number of cancers missed.


European Respiratory Journal | 2007

Factors determining early adherence to a lung cancer screening protocol

Usua Montes; Luis Seijo; Arantzazu Campo; Ana B. Alcaide; Gorka Bastarrika; Javier J. Zulueta

Lung cancer screening using computed tomography (CT) is effective in detecting early stage disease. However, concerns regarding adherence have been raised. The current authors conducted a retrospective observational study of 641 asymptomatic smokers enrolled in a lung cancer screening programme between 2000 and 2003. Adherent subjects were compared with nonadherent subjects with regard to lung function, sex, age, motivation for enrolment, smoking status, distance to the referral centre, family history of lung cancer, asbestos exposure, education, the presence and type of nodule(s) seen on initial CT, and exposure to a nursing intervention designed to improve adherence. Overall, early adherence to the study protocol was 65%. Multivariate analysis confirmed the importance of sex, proximity to the referral centre, the presence of noncalcified nodules, and the nursing intervention as factors conditioning adherence to the study protocol. Patients encouraged to participate in the study were more adherent, as were former smokers. Sex interactions were observed in multivariate analysis. The nursing intervention was significant for females, while abnormal lung function improved male adherence. Adherence to lung cancer screening is particularly good among females and subjects living near the referral centre. The present study suggests the need to develop new strategies, especially those targeting males and subjects with low risk perception, in order to improve adherence.


Archivos De Bronconeumologia | 2015

Cribado de cáncer de pulmón: catorce años de experiencia del Programa Internacional de Detección Precoz de Cáncer de Pulmón con TBDR de Pamplona (P-IELCAP)

Pablo Sanchez-Salcedo; Juan Berto; Juan P. de-Torres; Arantzazu Campo; Ana B. Alcaide; Gorka Bastarrika; Jesús C. Pueyo; Alberto Villanueva; Jose Echeveste; Maria D. Lozano; María José García-Velloso; Luis Seijo; Javier Garcia; Wenceslao Torre; Maria J. Pajares; Ruben Pio; Luis M. Montuenga; Javier J. Zulueta

INTRODUCTION AND OBJECTIVES European experience regarding lung cancer screening using low-dose chest CT (LDCT) is available. However, there is limited data on the Spanish experience in this matter. Our aim is to present the results from the longest ongoing screening program in Spain. METHODOLOGY The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) is actively screening participants for lung cancer using LDCT since year 2000 following the IELCAP protocol, including spirometric assessments. Men and women, ≥40 years of age, current or former smokers with a tobacco history of ≥10 pack-years are included. Results are compared to those from other European trials. RESULTS A total of 2989 participants were screened until March 2014 (73% male). A median of 2 (IQR 1-3) annual screening rounds were performed. Sixty lung cancers were detected in 53 participants (73% in StageI). Adenocarcinoma was the most frequent. The lung cancer prevalence and incidence proportion was 1.0% and 1.4%, respectively, with an annual detection rate of 0.41. The estimated 10-year survival rate among individuals with lung cancer was 70%. Chronic obstructive pulmonary disease and emphysema are important lung cancer predictors. CONCLUSIONS The experience in Spains longest lung cancer screening program is comparable to what has been described in the rest of Europe, and confirms the feasibility and efficacy of lung cancer screening using LDCT.


Lung Cancer | 2016

The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development

Pablo Sanchez-Salcedo; Juan P. de-Torres; Diego Martínez-Urbistondo; Jessica González-Gutiérrez; Juan Berto; Arantzazu Campo; Ana B. Alcaide; Javier J. Zulueta

OBJECTIVES Elevated neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratios (PLR) at time of cancer diagnosis have been associated to poor prognosis in various cancers. There is no data on their natural progression before the cancer diagnosis has been established. We aim to evaluate whether or not the annual changes in these ratios could be early indicators of lung cancer development. MATERIALS AND METHODS Participants recruited into the Pamplona International Early Lung Cancer Action Program (P-IELCAP, n=3061) between 2001 and 2015 were considered. Complete blood counts (CBC) were registered at annual intervals between enrolment and time of diagnosis. Linear regression was used to calculate the mean annual change in NLR and PLR in participants with ≥3CBCs. Changes were expressed relative to baseline values. Lung cancer incidence density and lung cancer risk (Cox regression analysis) were calculated for different NLR and PLR annual thresholds (<0%, ≥0%, ≥1%, ≥2%, ≥4%). Results were compared to a matched group of participants who did not develop lung cancer. RESULTS After a median follow-up of 80 months and a median of 4 (IQR 3-6) CBCs, subjects who developed lung cancer (n=32) showed greater NLR and PLR annual changes than matched controls (n=103) (2.56% vs. 0.27% [p=0.25] per year; and 3.75% vs. 0.33% [p=0.053] per year, respectively). Lung cancer incidence density per 100 person-years increased with higher annual NLR and PLR thresholds. On multivariable analysis (adjusting for emphysema and baseline lung-function), NLR and PLR were not significant lung cancer predictors. However, among individuals with emphysema, for each relative unit increase in PLR, lung cancer risk increased 5% (p=0.03). There was a significant supra-additive risk effect between PLR increase and emphysema. Annual NLR change was not a significant lung cancer predictor. CONCLUSION In a lung cancer screening setting, the assessment of annual PLR change could help predict lung cancer development.


Archivos De Bronconeumologia | 2015

Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).

Pablo Sanchez-Salcedo; Juan Berto; Juan P. de-Torres; Arantzazu Campo; Ana B. Alcaide; Gorka Bastarrika; Jesús C. Pueyo; Alberto Villanueva; Jose Echeveste; Maria D. Lozano; María José García-Velloso; Luis Seijo; Javier Garcia; Wenceslao Torre; Maria J. Pajares; Ruben Pio; Luis M. Montuenga; Javier J. Zulueta


European Respiratory Journal | 2014

Improving NLST criteria for lung cancer screening

Pablo Sánchez; Juan P. de-Torres; David O. Wilson; Joel L. Weissfeld; Arantzazu Campo; Ana B. Alcaide; Javier J. Zulueta


Monografías de Archivos de Bronconeumología | 2016

Factors determining the presence of osteoporosis in active and former smokers with and without Chronic Obstructive Pulmonary Disease

Pilar Rivera-Ortega; Jessica González-Gutiérrez; Patricia Restituto; Nerea Varo; Inmaculada Colina; Amparo Calleja; Mireya Pérez Rodríguez; Gorka Bastarrika; Ana B. Alcaide; Arantzazu Campo; Javier J. Zulueta; J.P. de Torres


European Respiratory Journal | 2015

Exploring the neutrophil/lymphocyte and platelet/lymphocyte ratios as biomarkers for lung cancer development

Pablo Sanchez-Salcedo; Jessica Gonzalez; Diego Martínez-Urbistondo; Juan Berto; Pilar Rivera; Esmeralda López-Zalduendo; Ana B. Alcaide; Arantzazu Campo; Juan P. de Torres; Javier J. Zulueta


European Respiratory Journal | 2013

Exploring the association betwen active hormonal life and the presence of emphysema/airway obstruction in female smokers

Juan Bertó Botella; Juan P. de Torres; Javier J. Zulueta; Arantzazu Campo; Ana B. Alcaide; Jorge Zagaceta; Pablo Sánchez; Pilar Rivero; Esmeralda López Zalduendo

Collaboration


Dive into the Arantzazu Campo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge